(Sharecast News) – GSK said on Friday that it has sold 270m shares in Haleon – the consumer health business it spun off last year – raising around £885.6m.
The company sold the shares in a placing to institutional investors at 328p each.
Following the settlement of the placing, GSK will hold 685m ordinary shares in Haleon, which represents a stake of 7.4%.
GSK and Pfizer, which has a 32% interest in Haleon, have each undertaken not to dispose of any further shares in Haleon for 60 days following settlement of the placing.
